サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：結合型ワクチンの世界市場：予測（2022年～2028年）
市場調査レポート
商品コード
1123160

結合型ワクチンの世界市場：予測（2022年～2028年）

Global Conjugate Vaccine Market Research and Forecast, 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 110 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
結合型ワクチンの世界市場：予測（2022年～2028年）
出版日: 2022年07月23日
発行: Orion Market Research
ページ情報: 英文 110 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の結合型ワクチンの市場規模は、予測期間中に10.2%のCAGRで拡大すると予測されています。肺炎球菌疾患の増加は、結合型ワクチン市場を大きく成長させています。血液感染症、耳感染症、敗血症の症例が世界的に増加していることが、世界の結合型ワクチン市場の成長に寄与しています。

当レポートでは、世界の結合型ワクチン市場について調査し、市場の概要とともに、製品タイプ別、疾患別、患者タイプ別、病原体別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析
  • COVID-19が主要参入企業に与える影響

第4章 市場セグメンテーション

  • 世界の結合型ワクチン市場、製品タイプ別
    • 多価結合型ワクチン
    • 一価結合型ワクチン
  • 世界の結合型ワクチン市場、疾患別
    • 髄膜炎菌
    • 三種混合（ジフテリア・百日咳・破傷風）
    • インフルエンザ
    • 肺炎球菌
    • その他
  • 世界の結合型ワクチン市場、患者タイプ別
    • 大人
    • 小児
  • 世界の結合型ワクチン市場、病原体別
    • 細菌結合型ワクチン
    • ウイルス結合型ワクチン
    • 混合ワクチン

第5章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Astellas Pharma Inc.
  • Astrazeneca
  • Bharat Biotech
  • Biological E Ltd.
  • Bavarian Nordic
  • CSL Behring
  • Daiichi Sankyo Company, Ltd.
  • Emergent BioSolutions, Inc
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Merck & Co.
  • Mitsubishi Tanabe Pharma Corp
  • Medimmune, LLC
  • Neuron Biotech
  • Novartis AG
  • Sanofi Pasteur
  • SutroVax Inc.
  • Pfizer, Inc.
  • Serum Institute Of India Pvt. Ltd
図表

LIST OF TABLES

  • 1. GLOBALCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYPRODUCT TYPE, 2021-2028($ MILLION)
  • 2. GLOBALMULTIVALENT CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL MONOVALENT CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 5. GLOBALCONJUGATE VACCINEFOR MENINGOCOCCAL, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBALCONJUGATE VACCINEFOR DIPHTHERIA TETANUS PERTUSSIS, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBALCONJUGATE VACCINEFOR INFLUENZAMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBALCONJUGATE VACCINEFOR PNEUMOCOCCAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBALCONJUGATE VACCINEFOR OTHER DISEASE, MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBALCONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 11. GLOBAL CONJUGATE VACCINE FOR ADULTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBALCONJUGATE VACCINE FOR PEDIATRICSMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
  • 14. GLOBAL BACTERIAL CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 15. GLOBALVIRAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 16. GLOBAL COMBINATIONCONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 17. GLOBAL CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICANCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. NORTH AMERICANCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYPRODUCT TYPE, 2021-2028 ($ MILLION)
  • 20. NORTH AMERICAN CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYDISEASE, 2021-2028 ($ MILLION)
  • 21. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 22. NORTH AMERICAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
  • 23. EUROPEANCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 24. EUROPEAN CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYPRODUCT TYPE, 2021-2028 ($ MILLION)
  • 25. EUROPEAN CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYDISEASE, 2021-2028 ($ MILLION)
  • 26. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 27. EUROPEAN CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)
  • 28. ASIA-PACIFICCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 29. ASIA-PACIFICCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYPRODUCT TYPE, 2021-2028 ($ MILLION)
  • 30. ASIA-PACIFIC CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYDISEASE, 2021-2028 ($ MILLION)
  • 31. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 32. ASIA-PACIFIC CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BYPATHOGEN TYPE , 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLDCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 34. REST OF THE WORLDCONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BYPRODUCT TYPE, 2021-2028 ($ MILLION)
  • 35. REST OF THE WORLD CONJUGATE VACCINEMARKET RESEARCH AND ANALYSIS BY DISEASE, 2021-2028 ($ MILLION)
  • 36. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATIENT TYPE, 2021-2028 ($ MILLION)
  • 37. REST OF THE WORLD CONJUGATE VACCINE MARKET RESEARCH AND ANALYSIS BY PATHOGEN TYPE, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBALCONJUGATE VACCINEMARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBALCONJUGATE VACCINEMARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBALCONJUGATE VACCINEMARKET, 2021-2028 (%)
  • 4. GLOBALCONJUGATE VACCINEMARKET SHARE BYPRODUCT TYPE, 2021 VS 2028 (%)
  • 5. GLOBALMULTIVALENTCONJUGATE VACCINEMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL MONOVALENTCONJUGATE VACCINEMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL CONJUGATE VACCINEMARKET SHARE BYDISEASE, 2021 VS 2028 (%)
  • 8. GLOBALCONJUGATE VACCINE FOR MENINGOCOCCALMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBALCONJUGATE VACCINEMARKET FOR DIPHTHERIA TETANUS PERTUSSIS SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL CONJUGATE VACCINE FOR INFLUENZA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBALCONJUGATE VACCINE FOR PNEUMOCOCCAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL CONJUGATE VACCINE FOR OTHERDISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PATIENT TYPE, 2021 VS 2028 (%)
  • 14. GLOBAL CONJUGATE VACCINE FOR ADULTS MARKET SHARE BY GEOGRAPHY 2021 VS 2028 (%)
  • 15. GLOBAL CONJUGATE VACCINEFOR PEDIATRICSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL CONJUGATE VACCINE MARKET SHARE BY PATHOGEN TYPE, 2021 VS 2028 (%)
  • 17. GLOBALBACTERIALCONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. GLOBAL VIRAL CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 19. GLOBAL COMBINATION CONJUGATE VACCINE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 20. US CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 21. CANADA CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 22. UKCONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 23. FRANCE CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 24. GERMANY CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 25. ITALY CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 26. SPAIN CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 27. REST OF EUROPE CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 28. INDIA CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 29. CHINACONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 30. JAPAN CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 31. SOUTH KOREA CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
  • 33. REST OF THE WORLD CONJUGATE VACCINEMARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2018306

Global Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product Type (Multivalent Conjugate Vaccines, Monovalent Conjugate Vaccines) By Disease (Meningococcal, Diphtheria Tetanus Pertussis, Influenza, Pneumococcal, and Others) By Patient Type (Adults and Pediatric) By Pathogen Type (Bacterial Conjugate Vaccine, Viral Conjugate Vaccine and Combination Vaccine) Forecast 2022-2028

The global conjugate vaccine market is anticipated to grow at a substantial CAGR of 10.2% during the forecast period. The increasing number of pneumococcal disease is significantly growing the market for conjugate vaccine. Conjugate vaccine can be used for several different infections. The growing cases of blood infection, ear infection, sepsis across the globe, are in turn contributing to the growth of the global conjugate vaccine market. For instance, according to WHO, report published on 8 September 2020, sepsis kills 11 million people each year, many of them children. Around half of the 49 million cases of sepsis each year occur among children, resulting in 2.9 million deaths.

The global conjugate vaccine market is segmented based on product type, disease, patient type and pathogen type. Based on product type the market is segmented into multivalent conjugate vaccines, and monovalent conjugate vaccines. Based on disease the market is bifurcated into meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and others. Based on patient type the market is segmented into adults and pediatric. Based on pathogen type the market is segmented into bacterial conjugate vaccine, viral conjugate vaccine and combination vaccine. Based on disease the diphtheria tetanus pertussis segment is anticipated to grow at the fastest rate, due to the rising number of respiratory problems among geriatric population, paralysis, heart failure which is fueling the global conjugate vaccine market. According to WHO, 1 in 200 infections leads to irreversible paralysis and among those paralyzed, 5% to 10% die when their breathing muscles become immobilized.

Geographically market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America dominates the market and is expected to continue its dominance over the forecast period. The growth can be attributed to the increasing number of infectious diseases and increasing adoption of conjugate vaccine. Due to awareness about meningococcal, diphtheria tetanus pertussis, influenza, pneumococcal, and other vaccine the demand for conjugate vaccine is set to increase over the coming years, which in turn, will contribute to the growth of the market in the North America region. According to Centre for Disease Control and Prevention(CDC), in the US, around 48.1% adults aged over 18 received influenza vaccinationin2019-2020..Further the presence of key market players is also growing the demand for the conjugate vaccine. Also, around 14.4 people have been killed due to pneumonia in US.

The major companies serving the global conjugate vaccine market are Merck & Co., GlaxoSmithKline Plc., Bharat Biotech and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, partnership, collaborations, fundings, and new product launches, to stay competitive in the market. For instance, in 2021Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial as per independent Monitoring Board recommendation.

Research Methodology

The market study of the global conjugate vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Conjugate vaccine Market Research and Analysis by Product Type

Global Conjugate vaccine Market Research and Analysis by Disease

Global Conjugate vaccine Market Research and Analysis by Patient Type

Global Conjugate vaccine Market Research and Analysis by Pathogen Type

The Report Covers

Comprehensive research methodology of the global conjugate vaccine market.

This report also includes a detailed and extensive market overview with key analyst insights.

An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.

Analysis of regional regulations and other government policies impacting the global conjugate vaccine market.

Insights about market determinants that are stimulating the global conjugate vaccine market.

Detailed and extensive market segments with the regional distribution of forecasted revenues.

Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the GlobalConjugate vaccineMarket
  • Recovery Scenario of GlobalConjugate vaccineMarket
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key CompanyAnalysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Ananlysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. GlobalConjugate VaccineMarket, by Product Type
    • 4.1.1. Multivalent Conjugate Vaccine
    • 4.1.2. Monovalent Conjugate Vaccine
  • 4.2. Global Conjugate Vaccine Market, by Disease
    • 4.2.1. Meningococcal
    • 4.2.2. Diphtheria Tetanus Pertussis
    • 4.2.3. Influenza
    • 4.2.4. Pneumococcal
    • 4.2.5. Others
  • 4.3. Global Conjugate Vaccine Market, by Patient type
    • 4.3.1. Adults
    • 4.3.2. Pediatric
  • 4.4. Global Conjugate Vaccine Market, by Pathogen type
    • 4.4.1. Bacterial Conjugate Vaccine
    • 4.4.2. Viral Conjugate Vaccine
    • 4.4.3. Combination Vaccine

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Astellas Pharma Inc.
  • 6.2. Astrazeneca
  • 6.3. Bharat Biotech
  • 6.4. Biological E Ltd.
  • 6.5. Bavarian Nordic
  • 6.6. CSL Behring
  • 6.7. Daiichi Sankyo Company, Ltd.
  • 6.8. Emergent BioSolutions, Inc
  • 6.9. Glaxosmithkline Plc.
  • 6.10. Johnson & Johnson
  • 6.11. Merck & Co.
  • 6.12. Mitsubishi Tanabe Pharma Corp
  • 6.13. Medimmune, LLC
  • 6.14. Neuron Biotech
  • 6.15. Novartis AG
  • 6.16. Sanofi Pasteur
  • 6.17. SutroVax Inc.
  • 6.18. Pfizer, Inc.
  • 6.19. Serum Institute Of India Pvt. Ltd